The complaint alleges that Aardvark Therapeutics failed to disclose critical safety risks associated with its flagship development program. Plaintiffs claim that management overstated the clinical and commercial potential of ARD-101, leading to false and misleading public statements throughout the class period. These alleged omissions came to light on February 27, 2026, when the company announced a voluntary pause of its Phase 3 HERO clinical trial.

Aardvark cited reversible cardiac observations identified during routine safety monitoring in a healthy volunteer study as the catalyst for the suspension. The market reacted sharply to the disclosure, sending Aardvark shares plummeting by 56.2%, or $7.02 per share, to close at $5.47 on March 2, 2026. The law firm Wolf Haldenstein Adler Freeman & Herz LLP is now representing investors seeking to recover losses linked to these events, citing the firm's history in securities litigation as a resource for those affected by the company's disclosures.